The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

NACompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

t:slim X2 with Control-IQ Technology & Dexcom G6 CGM

Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.

DEVICE

Sensor-augmented pump (SAP)

Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

22903

University of Virginia Center for Diabetes Technology, Charlottesville

55902

Mayo Clinic, Rochester

80045

Barbara Davis Center, University of Colorado, Aurora

93105

Sansum Diabetes Research Institute, Santa Barbara

94304

Stanford University, Stanford

02215

Harvard University (Joslin Diabetes Center), Boston

Sponsors
All Listed Sponsors
collaborator

Jaeb Center for Health Research

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Tandem Diabetes Care, Inc.

INDUSTRY

collaborator

DexCom, Inc.

INDUSTRY

collaborator

Roche Diagnostics GmbH

INDUSTRY

lead

University of Virginia

OTHER